The present invention discloses an engineered bacteriophage capable of binding to a commensal bacterium and inserting its genome polynucleotide into the commensal bacterium, but incapable of producing progeny, incapable of carrying out a lysogenic cycle and incapable of carrying out a lytic cycle within the commensal bacterium, wherein the engineered bacteriophage comprises a genome polynucleotide including at least one gene encoding at least one heterologous antigen(s) under the control of a promoter.

This invention relates to novel fusion peptides and immunogenic compositions containing the fusion peptides useful in the control and prevention of tick infestations. The invention also relates to compositions comprising said fusion peptides, methods of vaccination against tick infestation using said fusion peptides and compositions, and kits for use with such compositions and methods.

The present invention provides compositions and methods that can be used to determine a peptide signature for an antibody repertoire in a sample comprising multiple antibodies. The method can be used to characterize a phenotype in a sample, such as providing a diagnosis, prognosis or theranosis of a medical condition.

The present invention provides compositions and methods that can be used to determine a peptide signature for an antibody repertoire in a sample comprising multiple antibodies. The method can be used to characterize a phenotype in a sample, such as providing a diagnosis, prognosis or theranosis of a medical condition.

The present invention provides specific peptide biomarkers and sets of peptide biomarkers for use in methods of detecting or identifying bacterial biomarkers in a sample, wherein said bacterial biomarkers can be used to detect Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Escherichia coli, and/or Moraxella catarrhalis in a sample. Kits and diagnostic methods are also provided.

The present invention provides specific peptide biomarkers and sets of peptide biomarkers for use in methods of detecting or identifying bacterial biomarkers in a sample, wherein said bacterial biomarkers can be used to detect Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Escherichia coli, and/or Moraxella catarrhalis in a sample. Kits and diagnostic methods are also provided.

Methods and compositions useful in treating neurodegenerative disorders are based on septapeptides and extended forms thereof (or portions thereof) that exhibit chemokine activity with respect to microglial cell precursors.

Methods and compositions useful in treating neurodegenerative disorders are based on septapeptides and extended forms thereof (or portions thereof) that exhibit chemokine activity with respect to microglial cell precursors.

Provided are methods for one or more of the following: preventing, inhibiting, disrupting, dispersing or treating a polymicrobial biofilm comprising a Haemophilus bacteria in vitro and/or in vivo, such as in a subject in need thereof. The method comprises or consists essentially of, or yet further consists of contacting the polymicrobial biofilm with: (i) an anti DNA binding and bending protein (DNABII) antibody or a biologically active fragment thereof; and (ii) an anti majority subunit (PilA) of type IV pilus (T4P) antibody or a biologically active fragment thereof. Additionally, the methods may further comprise contacting the polymicrobial biofilm with an antibiotic optionally comprising a -lactam antibiotic or a sulfonamide antibiotic. Also provided are compositions and kits suitable for use in the methods.

The present disclosure is directed to a fusion protein comprising all or part of two or more Haemophilus influenzae (Hi) proteins selected from the group consisting of Omp26, P6, P4, PD and PF, wherein at least one of the Hi proteins thereof comprises a lipid moiety, and vaccines and immunogenic compositions comprising such fusion proteins. Methods of treating or preventing a disorder associated with an Hi infection in a subject are also provided.